US 12,257,271 B2
Holdermanella sp. bacterium and use thereof
Yolanda Sanz Herranz, Valencia (ES); Inmaculada Lopez Almela, Valencia (ES); Eva Ma Gomez Del Pulgar Villanueva, Valencia (ES); Alfonso Benitez-Paez, Valencia (ES); and Marina Romani Perez, Valencia (ES)
Assigned to CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), Madrid (ES)
Appl. No. 17/418,005
Filed by CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC), Madrid (ES)
PCT Filed Dec. 24, 2019, PCT No. PCT/ES2019/070882
§ 371(c)(1), (2) Date Jun. 24, 2021,
PCT Pub. No. WO2020/136301, PCT Pub. Date Jul. 2, 2020.
Claims priority of application No. ES201831282 (ES), filed on Dec. 26, 2018.
Prior Publication US 2022/0072064 A1, Mar. 10, 2022
Int. Cl. A61K 35/74 (2015.01); A23L 33/135 (2016.01); A61P 3/04 (2006.01); A61P 3/10 (2006.01)
CPC A61K 35/74 (2013.01) [A23L 33/135 (2016.08); A61P 3/04 (2018.01); A61P 3/10 (2018.01)] 8 Claims
 
1. A method for the treatment of diseases related to alterations in glucose metabolism, comprising administering an effective amount of the strain Holdemanella biformis with deposit number CECT 9752, or a composition comprising the strain Holdemanella biformis with deposit number CECT 9752 to a subject, wherein the disease related to alterations in glucose metabolism is selected from the list consisting of glucose intolerance, insulin resistance, metabolic syndrome, type 2 diabetes, and gestational diabetes.